← Eichor
Study identifier: NCT06753838 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)

Condition: Hemostasis  ·  Sponsor: Centre Hospitalier Universitaire Dijon

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.

This description comes directly from the study's public registry record.

Talk to the study team

Emmanuel De Maistre  ·  03 80 29 32 57  ·  emmanuel.demaistre@chu-dijon.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU Dijon BourgogneDijon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06753838